Novelix Pharmaceuticals Limited (BOM:536565)

Novelix Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	9.49	0.85	0.1	-0.6	-20.27	-37.64
Depreciation & Amortization	0.53	0.38	0.38	0.56	0.8	2.09
Other Amortization	-	-	-	-	0.22	0.02
Loss (Gain) From Sale of Assets	-	-	-	-	4.57	-
Loss (Gain) From Sale of Investments	-	-	-	-	15	-0.1
Other Operating Activities	0.05	0.23	-2.97	-5.14	4.6	-2.62
Change in Accounts Receivable	224.38	-225.94	3.3	-16.52	22.79	50.43
Change in Inventory	-27.35	3.51	-3.74	-2.89	-0.7	-0.2
Change in Accounts Payable	-355.24	84.12	-0.52	0.53	-11.15	3.94
Change in Other Net Operating Assets	2.66	-	-	-	-	-
Operating Cash Flow	-145.47	-136.85	-3.43	-24.05	15.86	15.93
Operating Cash Flow Growth	-	-	-	-	-0.42%	153.83%
Capital Expenditures	-10.73	-1.06	-	-0.04	-17.98	-0.3
Sale of Property, Plant & Equipment	-0.1	-	0.18	-	-	-
Investment in Securities	-	30.21	-1.39	22.84	15.08	-1.06
Other Investing Activities	0.34	0.16	3.07	-22.04	-4.69	2.71
Investing Cash Flow	-10.5	29.3	1.86	0.75	-7.6	1.36
Long-Term Debt Repaid	-	-	-	-	-	-7.67
Net Debt Issued (Repaid)	-	-	-	-	-	-7.67
Issuance of Common Stock	102.75	30.65	-	-	-	-
Other Financing Activities	66.2	82.5	-	-	-	-
Financing Cash Flow	168.95	113.15	-	-	-	-7.67
Miscellaneous Cash Flow Adjustments	0	0	0	-	-0	0
Net Cash Flow	12.98	5.61	-1.57	-23.3	8.26	9.62
Free Cash Flow	-156.21	-137.91	-3.43	-24.1	-2.12	15.63
Free Cash Flow Growth	-	-	-	-	-	199.65%
Free Cash Flow Margin	-18.40%	-44.87%	-7.58%	-125.49%	-2.38%	16.31%
Free Cash Flow Per Share	-12.48	-14.69	-0.33	-2.98	-0.26	1.93
Levered Free Cash Flow	-145.94	-159.47	4.48	10.27	-12.33	34.19
Unlevered Free Cash Flow	-145.94	-159.47	4.48	10.27	-11.97	34.53
Change in Working Capital	-155.55	-138.3	-0.96	-18.87	10.94	54.18

Source: S&P Global Market Intelligence. Standard template. Financial Sources.